Celgene (CELG ) Tops Q2 EPS by 4c, Raises FY EPS Guidance

Celgene (NASDAQ: CELG ) reported Q2 EPS of $1.23, $0.04 better than the analyst estimate of $1.19. Revenue for the quarter came in at $2.28 billion versus the consensus estimate of $2.26 billion.

Celgene sees FY2015 EPS of $4.75-$4.85, versus prior guidance of $4.60-$4.75 and the consensus of $4.79. Celgene sees FY2015 revenue of $9-9.5 million, versus the consensus of $9.24 million.

2015 Adjusted EPS Guidance Raised

• REVLIMID® net sales are expected to be in the range of $5.6 billion to $5.7 billion
• ABRAXANE® net sales are expected to be in the range of $1.0 billion to $1.25 billion
• GAAP diluted EPS is expected to be in the range of $2.17 to $2.46, lowered from the original range of $2.97 to $3

For earnings history and earnings-related data on Celgene (CELG ) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• CaliberCos Inc (CWD) Misses Q2 EPS by 43c; Offers Guidance